COSM Cosmos Health Inc.
Price Chart
Executive Summary
Cosmos Health issued a multi-year financial guidance press release projecting revenue growth from $65.3M in 2025 to $200.6M by 2029 (207% increase, 32% CAGR), with gross margins expanding from 12.1% to 35.5% and a transition to profitability by 2027. The projections are aspirational and lack near-term hard catalysts, making this a low-credibility forward-looking narrative for a $14M market cap company.
Key Financial Metrics
Actionable Insight
This is a multi-year aspirational guidance with no near-term hard catalyst. The projections are not backed by analyst consensus or near-term milestones. Monitor the 2026 quarterly results for signs of tracking toward the $90.5M revenue target. The CEO's insider buying provides some credibility, but the $14M market cap and historical volatility suggest caution. The LOI for a $11.5M revenue pharmacy network is a small near-term catalyst worth watching.
Key Facts
- 2025A revenue of $65.3M, up 20% YoY; gross profit up 83%; gross margin expanded 418 bps; cash rose >10x to $3.5M
- 2026E revenue guided to ~$90.5M (+39% YoY); 2029E revenue projected at $200.6M (32% CAGR)
- Gross profit projected to rise 801% to $71.2M by 2029; gross margin from 12.1% to 35.5%
- Net income projected to improve from ($19.1M) loss in 2025 to $31.0M profit by 2029; profitability expected in 2027
- Adjusted EBITDA projected from ($3.4M) in 2025 to $44.2M by 2029
- Operating cash flow projected positive in 2027 at $11.9M, growing to $24.0M by 2029
- Cash projected to increase 18x to $62.9M by 2029; all convertible notes expected to be fully repaid by 2026
- CEO Greg Siokas purchased >3.3M shares in 2025 and continued buying in 2026
- LOI to acquire a pharmacy distribution network generating ~$11.5M in annual gross revenue
- Athens real estate portfolio estimated fair market value of ~$15M being evaluated for monetization
Financial Impact
Multi-year revenue growth from $65.3M to $200.6M (207%); gross profit from $7.9M to $71.2M (801%); net income improvement of $50.1M
Risk Factors
- Multi-year projections are inherently speculative and not guaranteed; execution risk is high for a $14M market cap company
- Historical performance on COSM shows average T+20 call P&L of -5.75% and 33% win rate, indicating poor prior model calibration
- No near-term hard catalysts; the projections are aspirational and may not be achievable
- Company has history of losses ($19.1M net loss in 2025) and negative operating cash flow ($8.4M in 2025)
- Convertible debt overhang exists until full repayment by 2026; dilution risk remains
- Highly competitive nutraceutical and pharmaceutical distribution markets
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3301211 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 17, 2026
3d ago
|
Press Release
| $0.2417 $0.2129 | ▼ −11.92% | ▼ −12.70% | $0.2130 (−11.87%) |
|
Jun 12, 2026
8d ago
|
Press Release
| $0.2100 $0.2371 | ▲ +12.90% | ▲ +11.14% | $0.2130 (+1.43%) |
|
Jun 12, 2026
8d ago
|
Press Release
| $0.2100 $0.2371 | ▲ +12.90% | ▲ +11.14% | $0.2130 (+1.43%) |
|
Jun 10, 2026
10d ago
|
Press Release
| $0.2281 $0.2060 | ▼ −9.69% | ▼ −11.39% | $0.2130 (−6.62%) |
|
Jun 9, 2026
11d ago
|
Press Release
| $0.2233 $0.2281 | ▲ +2.15% | ▲ +3.73% | $0.2130 (−4.61%) |
|
Jun 8, 2026
12d ago
|
Press Release
| $0.2300 $0.2233 | ▼ −2.91% | ▼ −2.62% | $0.2130 (−7.39%) |
|
Jun 6, 2026
15d ago
|
S-3/A
| $0.2300 $0.2233 | ▲ +2.91% | ▲ +2.62% | $0.2130 (+7.39%) |
|
Jun 5, 2026
15d ago
|
DEFA14A
| $0.2300 $0.2233 | ▼ −2.91% | ▼ −2.62% | $0.2130 (−7.39%) |
|
Jun 1, 2026
19d ago
|
Press Release
| $0.2530 $0.2610 | ▲ +3.16% | ▲ +3.02% | $0.2130 (−15.81%) |
|
May 26, 2026
25d ago
|
Press Release
| $0.2630 $0.2650 | ▲ +0.76% | ▲ +0.75% | $0.2130 (−19.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access